Deutsche Bank’s Innate Pharma IPHA Stock Holding History

Deutsche Bank’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-100	Closed	-$1K	–	4338
2020 Q1	$1K	Buy	+100	New	+$674	﹤0.01%	4251

Other funds holding IPHA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Deutsche Bank's IPHA Position: Q2 2020 in Review

Deutsche Bank sold out of Innate Pharma (IPHA) in Q2 2020, closing a stake of 100 shares — an estimated $1K sold.

Deutsche Bank first reported a position in IPHA in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 7 funds tracked by Wall St. Rank hold IPHA as of Q2 2020.

Deutsche Bank reported no remaining Innate Pharma position as of Q2 2020 after selling out during the quarter.
Deutsche Bank sold 100 Innate Pharma shares in Q2 2020, an estimated $1K.
Deutsche Bank first reported a position in Innate Pharma in Q1 2020 and held it in 1 quarter.
Deutsche Bank's Innate Pharma position peaked at $1K in Q1 2020.
7 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2020.

Based on Deutsche Bank's 13F filing for Q2 2020, filed 13 Aug 2020.